anastrozol teva 1mg potahovaná tableta
teva pharmaceuticals cr, s.r.o., praha array - 14074 anastrozol - potahovaná tableta - 1mg - anastrozol
anastrozol mylan 1mg potahovaná tableta
mylan ireland limited, dublin array - 14074 anastrozol - potahovaná tableta - 1mg - anastrozol
anaprex 1mg potahovaná tableta
pharmagen cz s.r.o., praha array - 14074 anastrozol - potahovaná tableta - 1mg - anastrozol
atrocela 1mg potahovaná tableta
vipharm s.a., ożarów mazowiecki array - 14074 anastrozol - potahovaná tableta - 1mg - anastrozol
egistrozol 1mg potahovaná tableta
egis pharmaceuticals plc, budapešť array - 14074 anastrozol - potahovaná tableta - 1mg - anastrozol
alozex 1mg potahovaná tableta
glenmark pharmaceuticals s.r.o., praha array - 14074 anastrozol - potahovaná tableta - 1mg - anastrozol
anaya 1mg potahovaná tableta
heaton k.s., praha array - 14074 anastrozol - potahovaná tableta - 1mg - anastrozol
arimidex 1mg potahovaná tableta
laboratoires juvisé pharmaceuticals, villeurbanne array - 14074 anastrozol - potahovaná tableta - 1mg - anastrozol
zynzol 1mg potahovaná tableta
g.l. pharma gmbh, lannach array - 14074 anastrozol - potahovaná tableta - 1mg - anastrozol
verzenios
eli lilly nederland b.v. - abemaciclib - neoplasmy prsů - antineoplastická činidla - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.